Compare
GT Biopharma, Inc. vs Unicycive Therapeutics, Inc. vs Lifevantage Corp vs Scienture Holdings, Inc.
| Latest fiscal year | GT Biopharma, Inc. GTBP | Unicycive Therapeutics, Inc. UNCY | Lifevantage Corp LFVN | Scienture Holdings, Inc. SCNX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2026-06-30 | 2025-12-31 |
| Revenue | n/a | n/a | $182.59M | $431.6K |
| Revenue growth (YoY) | n/a | n/a | -20.1% | +215.9% |
| Gross margin | n/a | n/a | 77.6% | 76.8% |
| Operating margin | n/a | n/a | 3.3% | n/m |
| Net margin | n/a | n/a | 2.8% | n/m |
| Net income | -$28.35M | -$26.55M | $5.07M | -$41.51M |
| EPS (Diluted) | -$6.68 | -$1.67 | $0.40 | -$2.70 |
| Operating cash flow | -$12.91M | -$31.32M | $10.24M | -$13.38M |
| Free cash flow | n/a | -$31.34M | $6.67M | n/a |
| Cash & equivalents | $6.81M | $29.20M | n/a | $6.66M |
| Total assets | $8.11M | $49.13M | $62.11M | $84.18M |
| Total liabilities | n/a | $18.94M | $28.52M | $14.06M |
| Shareholders' equity | $5.79M | $30.20M | $33.59M | $70.12M |
| Return on year-end equity | -490.0% | -87.9% | 15.1% | -59.2% |
| Shares outstanding | 25.53M | 22.11M | 12.52M | 40.63M |
Revenue, most recent five fiscal years
| Fiscal year | GT Biopharma, Inc. | Unicycive Therapeutics, Inc. | Lifevantage Corp | Scienture Holdings, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $675.0K Ended 2023-12-31 | $182.59M Ended 2026-06-30 | $431.6K Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $951.0K Ended 2022-12-31 | $228.53M Ended 2025-06-30 | $136.6K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | $200.16M Ended 2024-06-30 | $1.36M Ended 2023-12-31 |
| 3 years earlier | n/a | n/a | $213.40M Ended 2023-06-30 | $10.25M Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | $206.36M Ended 2022-06-30 | $9.89M Ended 2021-12-31 |